TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including incretin therapies, to older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications to older adults with attention to age-related health needs. The guidance applies the Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapies, including GLP-1 medications, and stresses assessment of function, nutrition and cognition before treatment.
Published in the Journal of the American Geriatrics Society, the paper was developed by the AGS Healthy Aging Special Interest Group. It presents clinical cases as a practical way to consider how obesity treatment fits an older person’s health, daily function and priorities. The report describes potential benefits of these medicines for weight management and glycemic control, while emphasizing that older adults have been underrepresented in clinical trials.
The authors call for clinicians to assess functional status, nutritional adequacy and cognitive impairment before starting treatment. They also identify risks that may be especially relevant in older age, including frailty, sarcopenia, loss of lean muscle, malnutrition and dehydration. The framework is intended to prompt individualized decisions rather than treat age alone as a reason either to prescribe or to withhold medication.
The paper recommends pairing drug treatment with supportive measures, including resistance training and adequate dietary protein. Depending on a patient’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional. The source does not provide a single medication regimen or a universal eligibility threshold; its emphasis is on applying geriatric assessment and patient priorities to prescribing.
Balancing Weight Treatment With Function
Weight loss and blood-sugar management are not the only outcomes relevant to older patients. A prescribing decision may also affect strength, mobility and nutritional status, particularly for people already experiencing frailty or muscle loss. The framework makes these considerations part of the decision process, rather than focusing solely on weight or metabolic measures.
For patients, the approach supports discussions about what matters most to them and what monitoring or added support may be needed. For clinicians, it offers a structured way to consider competing health concerns and coordinate care. The article presents these points as guidance; it does not report that the framework has been tested in a trial or shown to improve patient outcomes.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
BowFlex Results Series SelectTech Dumbbells
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS 5Ms framework organizes geriatric care around Mind, Mobility, Medications, Multicomplexity and Matters Most. In this paper, the authors apply those domains to incretin therapy in older adults, using cases to help clinicians think through medication decisions alongside a patient’s wider circumstances.
The publication addresses a gap identified by the authors: older adults are underrepresented in clinical trials of obesity medications, while clinicians still need to make treatment decisions for this population. The report therefore focuses on careful assessment and patient-centered prescribing. It is a framework paper, not a new drug approval, clinical trial result or prescribing mandate.
“Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing”
— Elias M. Wisdom and co-authors, in the paper
Evidence and Individual Treatment Choices
The report does not establish how well the framework changes prescribing, safety or health outcomes, and the source material does not describe a clinical evaluation of the framework. It also does not set out one medication choice, dose or treatment duration for older adults. Because this group has been underrepresented in trials, the source does not resolve how risks and benefits vary across different older patients.
Specific decisions will depend on a person’s health, medications, nutritional status, functional abilities and goals. The report’s summary does not quantify the risk of muscle loss, malnutrition or dehydration, or specify monitoring intervals. These details should not be inferred from the framework’s general recommendations.
Putting the Framework Into Practice
The paper is now available in the Journal of the American Geriatrics Society. Its proposed next step is practical application by clinicians: assess an older patient’s function, nutrition and cognition before prescribing, then consider supportive measures and other professionals where appropriate. The source does not announce a rollout schedule, implementation program or follow-up study.
As clinicians use the framework, further research would be needed to determine whether this approach changes care or outcomes and to strengthen evidence about obesity medications in older adults. Patients considering these medicines should discuss individual benefits, risks and supportive care with a qualified health professional; the framework is not a substitute for personalized medical advice.
Key Questions
Who developed the framework?
The American Geriatrics Society Healthy Aging Special Interest Group developed the paper, led by Elias M. Wisdom and co-authors.
Which medications does it address?
The framework discusses obesity medications, including incretin therapies such as GLP-1 medications. The source does not name a single preferred drug or provide a universal regimen.
What should clinicians assess before prescribing?
The authors recommend assessing functional status, nutritional adequacy and cognitive impairment, while considering risks such as frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
What support may accompany medication?
The paper recommends considering resistance training and adequate dietary protein. Some patients may benefit from a team that includes nutrition, physical therapy, fitness or behavioral health professionals.
Does the framework prove these medications are safe for every older adult?
No. It offers a clinical decision framework, not proof of safety or benefit for every person. The source notes that older adults are underrepresented in clinical trials and does not report an evaluation showing that the framework improves outcomes.
Source: medicalxpress.com
